p53 gene (Gendicine) and embolisation overcame recurrent hepatocellular carcinoma.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 15879012.
- Also identified by PMC identifier 1774668.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Transcatheter arterial chemoembolisation (TACE) has become the standard treatment for unresectable hepatocellular carcinoma (HCC). However, this method is often unsuccessful. The p53 gene, which is present as a mutant form in many human tumours, is known to have broad spectrum antitumour effects when expressed normally. In this study, we report a 23 year old patient with recurrent HCC who was treated with the p53 gene (Gendicine) combining TACE, which resulted in a good clinical prognosis.
Medical subject headings
- Carcinoma, Hepatocellular
- Genes, p53
- Genetic Therapy
- Liver Neoplasms
- Neoplasm Recurrence, Local